Join us for an insightful on-demand webinar featuring Abigail Servais, PharmD, BCTXP, and Steve Kleiboeker, PhD, as they delve into a groundbreaking protocol at an academic medical center. This protocol incorporates serial assessment of CMV T Cell Immunity Panel (CMV-TCIP) to tailor valganciclovir prophylaxis duration for high-risk kidney transplant patients. Discover their findings on the risk of CMV disease following early discontinuation of prophylaxis and the predictors identified through CMV T cell immunity assessment.